SINTX Technologies Reports 74% Revenue Decline in Q3 2025, Net Loss Improves

SINTX Technologies, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $208,000, a significant decrease of 74% compared to $799,000 in the same period last year. For the nine months ending September 30, 2025, total revenue was $728,000, down 69% from $2.3 million in 2024. The decline in revenue was primarily attributed to the company's strategic shift away from low-margin OEM technical manufacturing contracts, which the company deemed unsustainable for long-term profitability. Product revenue for the quarter was $150,000, a 59% decrease from $367,000 in 2024, while grant and contract revenue fell to $58,000, down 87% from $432,000.

The company's operating expenses also saw a notable reduction, totaling $3.4 million for the third quarter, down 51% from $7 million in the same period last year. This decrease was largely due to the absence of armor exit costs, which had previously incurred $4.5 million in the prior year. Research and development expenses increased by 59% to $1.3 million, reflecting ongoing investments in product development, while general and administrative expenses surged by 162% to $2.1 million, driven by higher stock-based compensation and personnel costs. Despite these reductions in expenses, SINTX reported a net loss of $3.5 million for the quarter, an improvement from a net loss of $6.2 million in the same period last year.

In terms of strategic developments, SINTX Technologies received FDA 510(k) clearance for its SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025, marking its entry into the reconstructive foot and ankle surgery market. This product is expected to generate revenue in the first half of 2026. Additionally, the company completed the acquisition of Sinaptic Surgical, which involved issuing warrants for common stock and is anticipated to enhance SINTX's product offerings in the medical device sector.

Operationally, SINTX's cash and cash equivalents increased to $6.3 million as of September 30, 2025, up from $3.6 million at the end of 2024. The company reported a net cash used in operating activities of $6.2 million for the nine months ended September 30, 2025, a slight improvement from $7.5 million in the same period last year. The company continues to seek additional funding through equity and debt financing to support its operations and product development initiatives. Looking ahead, SINTX remains focused on leveraging its proprietary silicon nitride technology to drive growth in the biomedical sector, with an emphasis on developing innovative medical devices that address critical healthcare needs.